White paper: An outlook on U.S. biosimilar competition

Drugs of Today

Volumn 49, Issue 6, 2013, Pages 399-410

  Bourgoin, A F ^a   Nuskey, B ^a  

^a THOMSON REUTERS   (United States)

Author keywords

Biologics price competition and innovation act; Biosimilar user fee act; Biosimilars; Patient protection and affordable care act

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; ECULIZUMAB; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PALIVIZUMAB; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB; USTEKINUMAB;

ARTICLE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; LANDSCAPE; LEGAL ASPECT; PATENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRODUCT DEVELOPMENT; PUBLIC HEALTH SERVICE; SENSITIVITY AND SPECIFICITY; UNITED STATES; WORLD HEALTH ORGANIZATION;

BIOLOGICS PRICE COMPETITION AND INNOVATION ACT; BIOSIMILAR USER FEE ACT; BIOSIMILARS; PATIENT PROTECTION AND AFFORDABLE CARE ACT;

BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; PATENTS AS TOPIC; TERMINOLOGY AS TOPIC; UNITED STATES;

EID: 84880031596     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.6.2012938     Document Type: Article

References (16)

1. Taylor, L. First U.S. state biosimilars bill becomes law. Pharma Times Online, March 25, 2013.
2. Silverman, E. Never mind FDA, states are crafting biosimilar laws. Pharmalot.com, January 18, 2013.
3. Pollock, A. Biotech firms, billions at risk, lobby states to limit generics. New York Times, January 28, 2013.
4. Neas, R.G. Letter to Margaret Hamburg, MD. Generic Pharmaceutical Association, July 2, 2012.
5. Radcliffe, S., Wheadon, D.E. Letter to Margaret Hamburg, MD. Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America, June 25, 2012.
6. Amgen supports World Health Organization's proposed distinguishable naming policy for biosimilars [news release]. Amgen Inc., March 24, 2013.
7. Dolinar, R. It's all about the name: what is the imperative of adopting a unique names for biologic and biosimilar therapeutics? Food and Drug Policy Forum 2012, 2(22). November 28, 2012.
8. China to release biosimilar guidelines . Gabionline.net, November 23, 2012.
9. Biosimilar development. Sandoz Biopharmaceuticals Web site. http://www.sandoz-biosimilars.com/biosimilars/development.shtml.
10. Merck and Samsung Bioepis enter biosimilars development and commercialization agreement [news release]. Merck & Co., February 20, 2013.
11. Movers and Shakers: A Pharma Matters Reports. Thomson Reuters, February 2013.
12. Thomson Reuters Newport Premium.
13. Taylor, N. Teva eyes delivery devices to gain edge in biosimilar sector. In-Pharma Technologist.com, March 21, 2012.
14. Kulkarni, K., Foy, H. Pfizer scraps insulin deal with India's Biocon. Reuters, March 13, 2012.
15. Berkrot, B. Amgen biosimilar push takes aim at blockbusters. Reuters, February 7, 2013.
16. Mascarenhas, A. Trial for cheap medicine for rheumatoid arthritis soon. Indiaexpress.com, October 13, 2012.